Cargando…
ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups
BACKGROUND: The ATLAS trial, investigating adjuvant axitinib versus placebo in renal cell carcinoma (RCC), was stopped for futility at a preplanned interim analysis. We report subgroup outcome analyses by ethnicity, time on treatment, dose modification and toxicity. PATIENTS AND METHODS: Patient dem...
Autores principales: | Quinn, D.I., Ng, C.F., Grande, E., Kwon, T.G., Linke, R., Lee, J.-L., Rosbrook, B., Thakur, M.N., Eto, M., Gross-Goupil, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099745/ https://www.ncbi.nlm.nih.gov/pubmed/33901868 http://dx.doi.org/10.1016/j.esmoop.2021.100105 |
Ejemplares similares
-
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
por: Gross-Goupil, M, et al.
Publicado: (2018) -
Axitinib: A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma
por: Gross-Goupil, Marine, et al.
Publicado: (2013) -
Targeted treatments in advanced renal cell carcinoma: focus on axitinib
por: Verzoni, Elena, et al.
Publicado: (2014) -
Selenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity
por: Fu, Ying, et al.
Publicado: (2022) -
Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours
por: Hoh, C K, et al.
Publicado: (2014)